GlassScriptPhysician profile
David S Dunn
NPI 1700881315
$3,087.56
in general payments reported to CMS, 2019-2025
37 companies · $73.75 in 2025
The $73.75 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $308 · 2021: $527 · 2022: $477 · 2023: $477 · 2024: $640 · 2025: $73.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $596.75 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $301.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $240.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $232.25 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $219.16 | 2019-2024 | Vraylar |
| Lilly USA, LLC | $187.56 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $113.49 | 2023-2024 | Gemtesa |
| Dexcom, INC. | $101.97 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $88.58 | 2019-2024 | |
| Amgen INC. | $86.44 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $77.22 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $73.51 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.04 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Sunovion Pharmaceuticals INC. | $66.98 | 2019-2022 | |
| Exact Sciences Corporation | $58.85 | 2024 | Cologuard Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.